Squamous Cell Atypia Suggesting High-grade Lesions: Correlation of Morphological Data, HPV Test Results and Follow-up

Alameda F1,2, Hernández E1, Del Amo E1,2, Bellosoilo B1,3, Serrano L1 and Carreras R1,2

1Department of Pathology, and Obstetrics and Gynecology, Hospital del Mar, Barcelona, Spain
2Autonomous University of Barcelona, Spain
3Pompeu Fabra University, Barcelona Catalonina, Spain

Abstract

Background: Squamous cell atypia suggesting high-grade lesion (ASCH) is a cytological lesion, related to a high-grade lesion. Guidelines recommend performing a colposcopy in these cases, without HPV testing.

Objective: Here we sought to determine the value of the HPV test in ASCH cases and to correlate morphological data, the HPV test results, and the follow-up.

Methods: Ninety-six patients were diagnosed with ASCH using liquid-based cytology (Thin-Prep®). Hybrid Capture II was the HPV test used. The patients were followed up for 6 to 48 months (mean 24 months). The following cytological data were included: isolated cells; dyskeratosis; hyperchromasia; coarse chromatin; nuclear membrane irregularity and HSIL in the follow-up (p = 0.015); and molding and HSIL in the follow-up in HPV+ cases (p = 0.046).

Results: The mean age of the patients was 37 years (range 15-78). Thirty-seven cases were 30 years old or younger. Follow-up was not available for 11 cases. Seventy-two cases were HPV+. None of HPV- cases developed HSIL. The following cytological data showed statistical significance: coarse chromatin and HPV positivity (p = 0.007); nuclear membrane irregularity and HSIL in the follow-up (p = 0.015); and molding and HSIL in the follow-up in HPV+ cases (p = 0.046).

Conclusions: The HPV test is useful for ASCH cases. Some nuclear alterations in ASCH can predict HPV positivity and HSIL in the follow-up.

Keywords: Asch; HPV; Cytology; Morphology

Introduction

Squamous cell atypia suggesting high-grade lesion or ASCH is recognized by Bethesda [1]. It is diagnosed through a cytological smear which holds immature squamous cells or metaplastic cells in which cytological changes are suggestive but not conclusive of high-grade squamous lesion (HSIL). The criteria for ASCH were the same for HSIL but in ASCH cases not all the HSIL criteria are present. Thus, the differential diagnosis must be made in cases that mimic high-grade lesions, such as immature squamous metaplasia, atrophy with atypia, and cells with high nucleus/cytoplasm ratio. ASCH is a relevant [8,14-22]. In addition there are few studies that link the morphological/cytological features of ASCH with the HPV result and the follow-up of these patients [23,24].

Here we studied the value of the HPV test in an ASCH patient cohort. We sought to determine whether there is a relationship between the morphological/cytological changes of ASCH, the HPV test result, and the follow-up of the patients.

Materials and Methods

Ninety-six patients diagnosed with ASCH from January to December 2012 were included. All the patients had a HPV test. Furthermore, these patients were followed up for 6 to 48 months and they underwent colposcopy, cytology and biopsy. During the follow-up, all HSIL cases diagnosed by a smear test were biopsied, and these diagnoses were confirmed with p16 immunostaining.

For the cytological assessment, we used the ‘ThinPrep’ platform technical procedure with T-5000 (Hologic®, Malborough Mass.); automated staining of the slides with Leica® Autostainer (Leica®, Wetzlar, Germany), and automated reading of the slides using the ThinPrep Imager System (Hologic®, Malborough Mass.).

To determine the HPV status, Hybrid Capture II (HCII) (Qiagen, Limburg, the Netherlands) was used. HCIIHR (High-risk)-HPV TEST: Samples were previously treated with a conversion kit for this test, following the manufacturer’s instructions. HCII is based on nucleic
Results

Ninety-six patients were diagnosed with ASCH during the study period. The mean age of the patients was 37 (range 15-78). Thirty-seven cases were 30 years old or younger (38.5%) while 59 patients were over 30 (61.5%). We had access to follow-up data from 85 of these patients, 34 of them had 30 years or less and 51 patients had more than 30 years. Sixty six women were HPV positive.

In the analysis of HPV results, we observed that 86.5% of the younger women were HPV+ while only 67.8% of patients over 30 were HPV+ (p = 0.052) were shown in Table 1.

<table>
<thead>
<tr>
<th>AGE (years)</th>
<th>HPV</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>POS (%)</td>
<td>NEG (%)</td>
</tr>
<tr>
<td>≤30</td>
<td>32 (66.5)</td>
<td>5 (13.5)</td>
</tr>
<tr>
<td>&gt;30</td>
<td>40 (67.8)</td>
<td>19 (32.2)</td>
</tr>
<tr>
<td>TOTAL</td>
<td>72 (75)</td>
<td>24 (25)</td>
</tr>
<tr>
<td>P = 0.052</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1: Result of the determination of HPV by age.

Of the social-demographical factors studied, only civil status and the number of sexual partners were related to the development of HSIL during the follow-up Table 2.

<table>
<thead>
<tr>
<th>NATIONALITY (n = 94)</th>
<th>P = 0.76</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tobacco (n = 23)</td>
<td>P = 0.25</td>
</tr>
<tr>
<td>CC type (n = 75)</td>
<td>P = 0.36</td>
</tr>
<tr>
<td>Civil status (n = 55)</td>
<td>P = 0.03</td>
</tr>
</tbody>
</table>

Table 2: Socio-demographical factors related to HSIL in the follow-up.

| NATIONALITY: Spaniard/Non Spaniard; TOBACCO: Yes/no. CONTRACEPTIVE TYPE (CC): Type of contraception (Mechanical-hormonal/nocontraception); CIVIL STATUS: Married/non-married Sexual Partners: More or less than 10 partners. The results for patients with follow-up data are shown in Table 3.

<table>
<thead>
<tr>
<th>AGE (years)</th>
<th>HPV+</th>
<th>HPV-</th>
<th>Total</th>
<th>HPV+</th>
<th>HPV-</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤30 POS (32)</td>
<td>2</td>
<td>8 (25)</td>
<td>11 (42.3)</td>
<td>11 (40.7)</td>
<td>30 (35.3)</td>
<td></td>
</tr>
<tr>
<td>≤30 NEG (5)</td>
<td>1</td>
<td>2 (6.3)</td>
<td>2 (7.7)</td>
<td>0</td>
<td>4 (4.7)</td>
<td></td>
</tr>
<tr>
<td>&gt;30 POS (40)</td>
<td>4</td>
<td>12 (37.5)</td>
<td>8 (30.8)</td>
<td>16 (59.3)</td>
<td>36 (42.4)</td>
<td></td>
</tr>
<tr>
<td>&gt;30 NEG (19)</td>
<td>4</td>
<td>10 (31.3)</td>
<td>5 (19.2)</td>
<td>0</td>
<td>15 (17.6)</td>
<td></td>
</tr>
<tr>
<td>TOTAL POS (72)</td>
<td>6</td>
<td>20 (62.5)</td>
<td>19 (73)</td>
<td>27 (100)</td>
<td>66 (77.6)</td>
<td></td>
</tr>
<tr>
<td>TOTAL NEG (45)</td>
<td>5</td>
<td>12 (37.5)</td>
<td>7 (27)</td>
<td>0</td>
<td>19 (22.4)</td>
<td></td>
</tr>
</tbody>
</table>

Table 3: Follow-up data related to age and HPV test.

Sixty-six cases were HPV+ (77.6%) and 19 were HPV- (22.4%). Of all the patients, 58 did not develop high-grade lesions in the follow-up (68.2%), and of these, 26 cases developed low-grade lesions (44.8%) while 32 cases were negative in the follow-up (55.2%).

Results for HPV- cases (n = 19)

Four patients were 30 years old or younger and 15 patients were over 30. Seven of the 19 cases (36.8%) showed low-grade lesions in the follow-up (5 LSIL and 2 ASCUS), and 12 cases negative results (63.2%). None of the patients developed HSIL.

Results for HPV+ cases (n = 66)

Thirty patients were 30 years old or younger and 36 patients were over 30. During the follow-up, 27 patients (31.8%) developed high-grade lesions (CIN2-3) of whom 16 were over 30 (31.4%), and 11 under 30 (32.35%). Thirty-nine cases did not develop HSIL, although 19 of them had a low-grade lesion.

As mentioned above, none of the HPV- cases developed HSIL in the follow-up (p = 0.002, Table 4). The sensitivity of HPV test for HSIL in our series was 100%, the specificity 29.7%, the negative predictive value 100%, and the positive predictive value 31.8% (Table 4A and 4B).

Table 4: Sensitivity and specificity of HPV test for HSIL.
Table 4: Relationship between the HPV test and HSIL (a) or SIL (b) during the follow-up (A&B).

Fifty three cases developed an intraepithelial lesion of some kind in the follow-up (SIL): 46 in the HPV+ group and 7 in the HPV- group, which resulted in a statistically significance difference (p = 0.01). The sensitivity of the HPV test for a lesion of any grade was 86.8% the specificity 99.2%, the negative predictive value 69.7% and the positive predictive value 63.2%.

We studied the relationship between the morphological/cytological data and the HPV test (Table 5). Only coarse chromatin reached statistically significant association with the HPV test (p = 0.007), with a sensitivity of 100%, a specificity of 16.7%, a negative predictive value of 78.3%, and a positive predictive value of 100%. Regarding the morphological data in cases for which follow-up data was available, coarse chromatin was related with the HPV positivity (p = 0.007); Nuclear membrane irregularity showed a relationship with HSIL (p = 0.015 with a sensitivity of 100%, a specificity of 25%, a negative predictive value of 100%, and a positive predictive value of 30%) in all cases and in HPV positive cases (p = 0.003) (Table 5).

Table 5: Relationship between Morphological/Cytological Data, the HPV test, and the follow-up.

Molding was the morphological/cytological change related to HSIL in the follow-up (p = 0.046), only in HPV positive cases, but the sensitivity, specificity and predictive values were low (sensitivity: 47.6%; specificity: 75.6%; positive predictive value: 75.6%; negative predictive value: 47.6%).

Discussion

ASCH is a cytological category recognized by Bethesda [1]. At least one third of these cases may correspond to HSIL lesions in the biopsy [13].

Some authors have emphasized the importance of ASCH diagnoses because they are closely related to HSIL lesions in the follow-up [2-12]. In addition, the relevance of HPV test has been reported for these cases as most of the HSIL that patients present during the clinical follow-up is strongly related to HPV positivity [8,14-22]. The present study highlights the importance of high negative predictive value of the HPV test in ASCH cases. Thus, we recommend that the HPV test be used for the management of patients with ASCH.

In our study, the incidence of HSIL during the follow-up was lower than that reported in previous studies (24.7% vs. 28.3% to 65.5% reported) [2-6,8-10,23,24]. This finding could be attributed to underdiagnoses in our center. However, we also used a HPV test. In this regard, we believe that this test is of clinical use because all the HSIL cases were HPV+.

Regarding the age of the patients, the cases showed only a marginally significant difference with respect to the HPV test, but not related to high-grade lesions. Cervical lesions (of any grade) have been reported to be more frequent in women under 30 [2]. Moreover, those authors demonstrated that the incidence of HSIL is greater in younger women. However, our data are not consistent with those described in the literature either not related as the HPV-related cases (younger vs. older: SIL: 22 vs. 24 cases, SIL/HPV+: 24 vs. 28 cases, respectively).

Among socio-demographical factors, we found no correlation with the development of HSIL during follow-up and smoking, nationality and contraception. The civil status (non-married vs. married) and the number of partners (more or less than 10) correlated in a statistically significant manner with the development of HSIL in the follow-up.

Finally, related to morphological/cytological data, our results show that some of the data are associated with the positivity of the HPV test (coarse chromatin) (Figure 1).

Molding was the morphological/cytological change related to HSIL in the follow-up (p = 0.046), only in HPV positive cases, but the sensitivity, specificity and predictive values were low (sensitivity: 47.6%; specificity: 75.6%; positive predictive value: 75.6%; negative predictive value: 47.6%).

Figure 1: ASCH. Coarse chromatin Papanicolau X20.
Conclusions

The HPV test has a predictive value for the follow-up of ASCH cases. There are the following associations between some morphological/cytological details in ASCH, the HPV test result, and the development of HSIL: coarse chromatin and HPV test result; nuclear membrane irregularity and HSIL in the follow-up, molding and HSIL in the follow-up in HPV+ cases.

References


